I recently attended the Alzheimer’s Disease Keystone meeting in Keystone, CO and became more acutely aware of something than ever before: academia and drug companies really like one another. Sure, the latter always loved the former, since collaborating with university-based scientists often made the publications arising from the private sector look a little more legit. On the contrary, the reciprocity in this relationship has not always been there. There is without a doubt some sub-disciplinary differences in this complex relationship, but in the basic science departments that I lurked around, if you were associated with a company (or worse, left academia for a position there, succumbing to the power of the Dark Side), there was always talk of whether or not you could be trusted.  Read more

I would say no. Grant proposals are a precious commodity, especially in this day and age of reduced funding and evaporating money. However, in a recent Nature correspondence, Dr. Noam Harel describes his vision for a centralized grant repository, ideally open to the public, where researchers could place their best ideas, allowing various funding agencies to discover the plans most-suited to their respective agendas. Dr. Harel likens this potential web manifestation to something like eBay, Facebook or Google, but for scientists and funding agencies. A more apt analogy might be Monster.com, with both sides searching for their ideal match, and a long-term relationship (perhaps I am now making it sound more like eHarmony.com…).  Read more